tbuckley/cabot-search huggingface dataset:
Efficacy of Local Treatment in Prostate Cancer Patients with Clinically Pelvic Lymph Node-positive Disease at Initial Diagnosis
Authors: Thomas Seisen, Malte W. Vetterlein, Patrick Karabon, Tarun Jindal, Akshay Sood, Luigi Nocera, Paul L. Nguyen, Toni K. Choueiri, Quoc-Dien Trinh, Mani Menon, Firas Abdollah
Journal: European Urology (2017)
Lenalidomide (REV) in asymptomatic late recurrent ovarian cancer (ROC) patients with increasing CA 125: A GINECO phase II trial.
Authors: Frédéric Selle, Isabelle Ray-Coquard, Emmanuel Sevin, Véronique Mari, Dominique Berton-Rigaud, Hugues Pierre Bourgeois, Nadine Dohollou, Michel Fabbro, Anne Floquet, Anne Lesoin, Alain Lortholary, Anne-Claire Hardy-Bessard, Jean-Louis Misset, Marie-Ange Mouret-Reynier, Eric Pujade-Lauraine
Journal: Journal of Clinical Oncology (2012)

5018 Background: REV is a thalidomide analogue, with both immunomodulatory and anti-angiogenic properties that could confer antitumor effect in ROC. Methods: The aim of this study was to evaluate REV efficacy as single agent in patients (pts) with asymptomatic late ROC (&gt;6mos) with increasing CA 125, in 2nd or 3rd line. Primary endpoint was to estimate the rate of non-progressive disease at 4 mos. Pts were treated with REV 20 mg daily in oral continuous regimen with systematically recommended anti-thrombotic prophylaxis (ATP). Imagery and CA 125 were performed every 8 weeks. Results: From 05/2009 to 09/2010, 45 pts were included with a median age of 63 years. Pt characteristics were: serous (78%), previous lines (one 73%, two 27%), median platinum-free interval (PFI) (11.3 mos), PFI &gt; 12 mos (42%), measurable disease (73%), and ECOG performance status 0 (84%). Efficacy: Rate of non progressive disease at 4 mos was 38% (95%CI, 23-53), 59 % (95%CI, 36-82) and 24 % (95%CI, 7-41) for the global population, pts relapsing over 12 mos and those relapsing between 6-12 mos, respectively. Results were independent of the number of previous lines. Median progression-free survival was 3.8 mos (95%CI, 2.1-5.6) and 6.4 mos in the subset of pts with PFI &gt; 12 mos. Response evaluation according to CA 125 (Rustin criteria) was: complete response (CR) 2.4%, partial response (PR) 17%, stable disease (SD) 71%. When using RECIST criteria alone, response evaluation was: 9.5% PR and 45% SD. Median duration of biological response was 6.6 mos. REV efficacy will be correlated to immunological parameters (lymphocyte phenotypes and cytokines). Safety: Grade 3-4 toxicity in more than 5% of pts was neutropenia (29%) and thrombo-embolic events (TEE) (11%). TEE occurred only in pts without ATP. Reasons for stopping treatment due to toxicity were TEE (3), allergy (2), arrhythmia (1), dyspnea (1) and neutropenia (1). Conclusions: REV demonstrated encouraging activity in ROC with good tolerability and manageable adverse events. A phase I of REV combined with platinum-based chemotherapy is currently being conducted.
A randomized controlled phase <scp>II</scp> clinical trial comparing <scp>ONO</scp>‐4053, a novel <scp>DP</scp>1 antagonist, with a leukotriene receptor antagonist pranlukast in patients with seasonal allergic rhinitis
Authors: K. Okubo, K. Hashiguchi, T. Takeda, K. Baba, H. Kitagoh, H. Miho, H. Tomomatsu, S. Yamaguchi, M. Odani, H. Yamamotoya
Journal: Allergy (2017)

Abstract Background Prostaglandin D 2 ( PGD 2 ) is primarily produced by mast cells and is contributing to the nasal symptoms including nasal obstruction and rhinorrhea. Objective This study aimed to evaluate the efficacy and safety of a novel PGD 2 receptor 1 ( DP 1) antagonist, ONO ‐4053, in patients with seasonal allergic rhinitis ( SAR ). Methods This study was a multicenter, randomized, double‐blind, parallel‐group study of patients with SAR . Following a one‐week period of placebo run‐in, patients who met the study criteria were randomized to either the ONO ‐4053, leukotriene receptor antagonist pranlukast, or placebo group for a two‐week treatment period. A total of 200 patients were planned to be randomly assigned to receive ONO ‐4053, pranlukast, or placebo in a 2:2:1 ratio. Nasal and eye symptoms were evaluated. Results Both ONO ‐4053 and pranlukast had higher efficacy than placebo on all nasal and eye symptoms. ONO ‐4053 outperformed pranlukast in a total of three nasal symptom scores (T3 NSS ) as well as in individual scores for sneezing, rhinorrhea, and nasal itching. For T3 NSS , the Bayesian posterior probabilities that pranlukast was better than placebo and ONO ‐4053 was better than pranlukast were 70.0% and 81.6%, respectively, suggesting that ONO ‐4053 has a higher efficacy compared with pranlukast. There was no safety‐related issue in this study. Conclusions We demonstrated that the efficacy of ONO ‐4053 was greater than that of pranlukast with a similar safety profile. This study indicates the potential of ONO ‐4053 for use as a treatment for SAR (Japic CTI ‐142706).
Evaluation of Various Strategies to Generate NPM1mut-Specific T Cell Clones
Authors: Elke Ruecker-Braun, Falk Heidenreich, Cornelia S Link, Maria Schmiedgen, Rebekka Wehner, Denise Kühn, Katharina Heidrich, Nael Alakel, Marc Schmitz, Christian Thiede, Gerhard Ehninger, Martin Bornhäuser, Johannes Schetelig
Journal: Blood (2016)
Readmission after gastrectomy for cancer: Pattern and incidence
Authors: R. F. Saidi, P. S. Dudrick
Journal: Journal of Clinical Oncology (2004)

4273 Background: Readmission after hospital discharge is an undesirable event with adverse affect on patient outcome. Our objective was to define the prevalence, patterns and predisposing characteristics for hospital readmission after gastrectomy and relate readmission to outcome. Methods: Clinical data for patients undergoing gastrectomy over a ten-year period were analyzed retrospectively. Readmits, defined as inpatient admission after operation, were divided into surgery-related (SR) and cancer-related (CR). Results: Twenty patients (44.4%) were readmitted. There were a total of 29 readmits: 12 (60%) had only one readmit, 7 (35%) had two, and 1 (5%) had three readmits. Eighteen (62%) of the readmits were due to SR and 11 (38%) were due to CR problems. Four (20%) because of CR (mostly malignant pleural effusion). Median hospital stay and hospital-free survival after discharge were 8 and 20 days respectively. Twelve (60%) of the patients were readmitted for SR such as dumping syndrome (n = 7), fistula (n = 2) and gastrointestinal obstruction (n = 2). Median hospital stay was 9 days and median hospital-free survival after discharge was 15 months. Four Patients (20%) were readmitted for both CR and SR. There was no difference between readmitted vs. not-readmitted patients regarding age, type of operation, operative morbidity, and comorbidity. Two-thirds of patients readmitted had Stage III or IV disease compared to 21.8% of those who were not readmitted (p=0.009). Overall patient 2-year survival was 48%; 45% for those with SR and 25% for CR readmits. Conclusions: Hospital readmission after gastrectomy for cancer is common. Those who were readmitted tended to have more advanced disease. Survival after CR readmission was limited. Readmission after SR had no affect on patient survival. No significant financial relationships to disclose.
Multidisciplinary cancer conferences as a forum for early identification of patients who can benefit from a palliative approach to care: INTEGRATE quality improvement project.
Authors: Frances Catriona Wright, Sandy Buchman, Marnie MacKinnon, Erin Arthurs, Yanchini Rajmohan
Journal: Journal of Clinical Oncology (2017)

196 Background: Introducing palliative care early in the cancer journey results in a better quality of life, less aggressive care and longer survival compared to patients receiving standard care. The INTEGRATE project goal is to identify and manage patients who may benefit from palliative care earlier in their care. Multidisciplinary cancer conferences (MCCs) are scheduled meetings for oncology teams to prospectively discuss patient diagnostic tests and treatment options. In this study, we tested whether MCCs could be used as a forum to identify patients using the UK Gold Standards Framework Surprise Question (Would you be surprised if this person died within the next year?). Methods: Cancer centres volunteered to participate in a pilot project to test the efficacy of the Surprise Question at MCCs and implement a palliative model of care. Prior to initiation, a survey was completed to identify provider comfort in providing palliative care. All sites received primary level palliative care education by completing Pallium Canada’s LEAP Oncology module. Identified patients received Advance Care Planning, symptom management, referrals and standardized reporting to primary care. Results: A baseline survey showed over 50% of providers had no palliative care training. 157 providers participated in LEAP Oncology. Three MCC disease sites (Lung, GI and CNS) are participating in 3 academic and 1 non-academic cancer centres. Implementation of the Surprise Question began in February 2015 and by August 2016, 300 patients were identified out of 1086 total reviewed patients. At the CNS MCC, 100% of all glioblastoma patients were identified. The Lung and GI sites had lower identification rates (19% and 19%, respectively). Identified patients will have their healthcare utilization (community referrals, billing patterns, etc.) analyzed and final results will be synthesized by project completion in January 2017. Conclusions: MCCs appear to be an excellent forum for identifying patients who may benefit from a palliative approach to care within CNS, Lung and GI site groups. Further analysis will inform broader palliative care recommendations in Ontario.
Female college students knowledge, attitudes and practices about breast-self examination and behavioral-related risk factors for breast cancer: A cross-sectional analysis.
Authors: Jorge Enrique Correa Bautista, Jose F Meneses-Echavez, Robinson Ramirez-Velez
Journal: Journal of Clinical Oncology (2015)

e12575 Background: Breast cancer is a growing public health problem worldwide. Breast-self examination (BSE) is an inexpensive strategy proposed to improve early detection behaviors. Behavioral risk factors are crucial for cancer control. More than half of breast cancer cases can be prevented through behavior change. This study aimed to describe and establish assocations between the knowledge, attitudes and practices of breast-self examination, the knowledge about breast cancer risk and behavioral-related risk factors for breast cancer among female college students in Bogotá, Colombia. Methods: A cross-sectional study was carried out involving data from 628 young female students. Data for BSE were collected using a validated tool and the Behavioral Risk Factors Surveillance System (BRFSS) was used for lifestyle-related variables. Results: Women were a mean age of 21.7±11.8 years old. Fifty-seven percent of the women knew how to carry out BSE, although only 26.3% perfom it monthly. Further, a sedentary lifestyle was found in 53.3% of women and similar prevalences were observed for other behavioral variables. BSE was associated with age (p = 0.02), socioeconomic status (p < 0.001), knowledge about risk factors (p < 0.001) and unhealthy lifestyles (p < 0.001). Conclusions: There exists a low level of knowledge and practice of BSE among female college students. This population is at a high-risk of breast cancer beacuse of the critical prevalences of some behaviors related to unhealthy lifestyles found in this study. Further health-promotion strategies are warranted.
Medication reconciliation in cancer day hospital.
Authors: Elena Tenti, Andrea Casadei Gardini, Alessio Schirone, Alessandro Passardi, Martina Minguzzi, Elena Prati, Dino Amadori
Journal: Journal of Clinical Oncology (2015)

e17748 Background: With the context of medication reconciliation, a vital role is played by the patient in keeping a careful track of all aspects of his/her healthcare. The first step is to obtain a complete list of a patient’s medications, a process involving both patient and relatives in a cancer setting where healthcare is necessarily patient- and family-centered. The purpose of this study was to evaluate a reconciliation questionnaire designed to collect information on drugs taken at home by cancer patients. Methods: From 1-31 October 2014, a reconciliation questionnaire was distributed by oncology pharmacist to 100 adult patients undergoing infusion therapy in the Day Hospital of our cancer center (IRST IRCCS). Results: There were 58 males and 42 females in the study. Mean age was 61.3 years. 84% of patients completed the form alone, 13% requested the help of an oncology pharmacist and 3% were assisted by their caregivers. A total of 450 drugs were being taken at home of which 92% were oral therapies and 8% intravenous. The average number of drugs being taken at home was 4.22 and only 54% of patients were able to explain why they were taking these drugs. 86% of the drugs had been prescribed by a specialist and 8% by a general practitioner, 2% were self-medications or had been recommended by friends, and the prescriber of the remaining 4% was not indicated. 22% of patients were taking a beta-blocker, 22% a proton pump inhibitor, 10% an anti-inflammatory agent , 9% a corticosteroid and 9% a diuretic. Conclusions: Important information was obtained about the therapies taken by cancer patients at home, all 100 patients responding positively to the initiative. Our results also confirmed that the close collaboration between oncology pharmacists and dedicated nursing staff led to enhanced patient empowerment and sense of responsibility regarding treatment adherence.
Rate of Persistent Postconcussive Symptoms
Authors: Garrett R. Young, Jack W. Tsao
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
AML Cells Have Altered Mitochondrial Biogenesis and Low Spare Reserve Capacity in Their Respiratory Chain That Renders Them Susceptible to Oxidative Metabolic Stress.
Authors: Shrivani Sriskanthadevan, Timothy E Chung, Marko Skrtic, Bozhena Jhas, Rose Hurren, Marcela Gronda, Xiao Ming Wang, Yulia Jitkova, Mahadeo A. Sukhai, Feng-Hsu Lin, Neil Maclean, Rob C. Laister, Peter Mullen, Stephanie Xie, Linda Penn, Ian M. Rogers, John E. Dick, Mark D. Minden, Aaron D Schimmer
Journal: Blood (2012)
Behind the Scenes: Endo/Exocytosis in the Acquisition of Metastatic Traits
Authors: Letizia Lanzetti, Pier Paolo Di Fiore
Journal: Cancer Research (2017)

Abstract Alterations of endo/exocytic proteins have long been associated with malignant transformation, and genes encoding membrane trafficking proteins have been identified as bona fide drivers of tumorigenesis. Focusing on the mechanisms underlying the impact of endo/exocytic proteins in cancer, a scenario emerges in which altered trafficking routes/networks appear to be preferentially involved in the acquisition of prometastatic traits. This involvement in metastasis frequently occurs through the integration of programs leading to migratory/invasive phenotypes, survival and resistance to environmental stresses, epithelial-to-mesenchymal transition, and the emergence of cancer stem cells. These findings might have important implications in the clinical setting for the development of metastasis-specific drugs and for patient stratification to optimize the use of available therapies. Cancer Res; 77(8); 1813–7. ©2017 AACR.
Prognostic significance of EGFR, erbB-2 and p53 expression in advanced cervix cancer patients treated with concurrent radiochemotherapy
Authors: J. Perez-Regadera, A. Sanchez-Muñoz, J. de la Cruz Bértolo, C. Ballestin, R.M. Garcia Martin, P Ferrando, C Mendiola, E Lanzos
Journal: Journal of Clinical Oncology (2004)

5035 Background: Radiochemotherapy has improved the outcome of patients with advanced cervix cancer. Nevertheless, nearly half of the patients die due to the disease. Objective: To describe the prognostic significance of EGFR, erbB-2 and p53 protein expression. Methods: Follow-up study of patients with advanced cervical cancer (n=73) [FIGO Stages IB-IIA (n=4), IIB (n=15), IIIB (n=40), IVA (n=11), IVB* (n=3) (*enlarged lymph nodes in paraortic area in CT scan); Histology: squamous (n=66), adenocarcinoma (n=5), mixed (n=2)]. All patients received pelvic (+/–paraortic) radiotherapy, brachitherapy if possible, and concurrent chemotherapy (two protocols during the study period: 1) December 1994-May 1999: tegafur (800 mg/day per os); 2) May 1999- January 2003 tegafur (same doses) plus 5–6 cycles of weekely cisplatin 40 mg/m2. Immunohistochemical (IC) methods were used to determine EGFR, erbB-2 and p53 levels in biopsies. EGFR and erbB-2 were considered positive if = 70% of cancer cells were stained; p53 was positive if >15%. Patients were classified in 3 categories according to a combination of IC measurements: 1) EGFR negative independent of erb-B2 and p53 status; 2) EGFR positive and only one of the other markers positive; 3) EGFR positive, erbB-2 positive and p53 positive. Survival probability distributions for cause-specific mortality were estimated with Kaplan-Meier methods and compared with Log-rank test. Results: Conclusions: Overexpression of EGFR may have a poor prognosis significance for patients with advanced cervix cancer. Patients with EGFR, erbB-2 and p53 simultaneously positive showed the less favourable cause-specific survival probability. No significant financial relationships to disclose.
A multidisciplinary effort to decrease time from admission to chemotherapy on an inpatient oncology unit.
Authors: Louise Ming-Wai Man, Jeremy Sen, Jeanne Cahan, Kathlene Degregory, Tanya Thomas, Elizabeth Daniels, Erin McLoughlin, Lisa Huntsinger, Michael Kenneth Keng
Journal: Journal of Clinical Oncology (2017)

96 Background: Patients with established cancer diagnoses often experience delays in starting scheduled inpatient chemotherapy (CTX) after arrival on the University of Virginia (UVA) Medical Center oncology unit. These delays negatively impact hospital resource utilization. We formed a multidisciplinary team of physicians, nurses, and pharmacists to investigate these delays. We aim to decrease time-to-CTX (TTC) by 30% from baseline. Methods: From 340 planned inpatient CTX encounters in calendar year 2015, 100 were randomly reviewed to establish baseline retrospective data. The following were collected for each encounter: patient demographics; oncologic diagnosis; admitting team; CTX regimen and cycle; procedures and urinary parameters required prior to CTX start; times of lab orders and results, CTX signature and release, and start of intravenous fluid (IVF), premedications, and CTX; unit census data; available nursing staff; and length of stay. With guidance from ASCO’s Quality Training Program, we constructed a process map of the current state, an Ishikawa cause-and-effect diagram, a Pareto chart to assess causes of delays, and a priority matrix of potential interventions. XmR charts compared baseline and post-intervention data. Results: Baseline median TTC was 6.7 hours (range 1.5-105.3 h). Patients with pre-admission outpatient appointments started CTX 2.4 h earlier than those without appointments. Patients without urine parameters for treatment started CTX 3 h earlier than those with parameters. The Pareto chart indicated the longest delays occurred in pre-medicating patients, starting IVF, and signing CTX orders. In the first Plan-Do-Study-Act (PDSA) cycle, the CTX consent process was reformed. Post-intervention data showed no change in median TTC (7.2 h). Other PDSA cycles (setting patient arrival times and pre-admission pharmacy review of treatment plans) are ongoing; prospective data collection is pending. Conclusions: Retrospective data validate concerns that delays in starting inpatient CTX are longer than acceptable. They affect hospital length of stay, cost, and patient satisfaction. Our first PDSA cycle showed no change in TTC but additional interventions are ongoing.
Abstract 055: β-Catenin Mediates an Interplay between Genetic Background and Growth-Regulating Effects of Estrogen in the Healthy Heart
Authors: Georgios Kararigas, Ba Tiep Nguyen, Laura C Zelarayan, Maike Hassenpflug, Karl Toischer, Hugo Sanchez-Ruderisch, Gerd Hasenfuss, Martin W Bergmann, Hubertus Jarry, Vera Regitz-Zagrosek
Journal: Circulation Research (2013)

In diseased hearts, estrogen (E2) has been shown to exert anti-hypertrophic actions. Little is known about the role of E2 in the healthy heart. Our initial aim was to characterize structurally and molecularly the effects of E2 in the healthy mouse heart. Two-month-old female C57Bl/6J mice were ovariectomized and randomized to an E2-containing or soy-free (control, CON) diet ( n = 17-18/group). The three-month physiological dose of E2 led to a higher relative heart weight compared with CON ( P &lt; 0.001). We also confirmed increased cardiomyocyte cross-sectional area by E2 ( P &lt; 0.01). No activation of the fetal gene program and no fibrosis were observed. Transcriptome analysis revealed induction of growth-related pathways by E2, such as the Wnt signaling pathway ( n = 5/group; adjusted P &lt; 0.05). To further confirm activation of Wnt/β-catenin signaling, we verified increased nuclear β-catenin protein levels by E2 compared with CON ( P &lt; 0.01) and hypothesized that β-catenin mediates the actions of E2. Cardiac deletion of β-catenin blunted the E2 effects on cardiac growth ( n = 13/group). Surprisingly, in wild-type littermates with the background C57Bl/6N, E2 decreased the relative heart weight and cardiomyocyte cross-sectional area compared with CON ( n = 7-11/group; P &lt; 0.001). This was underlain by decreased nuclear β-catenin protein levels by E2 compared with CON ( P &lt; 0.001). Furthermore, E2 increased glycogen synthase kinase 3β (GSK3β) phosphorylation and the endosomal/autophagosomal markers Rab5, Rab7 and LC3-II in C57Bl/6J but not C57Bl/6N mice. Assessing a polymorphism linked to Snap29 , we confirmed higher Snap29 protein levels in C57Bl/6J than C57Bl/6N mice ( P &lt; 0.01). This could lead to distinct regulation of endosomes and could be the potential cause of the strain difference. In conclusion, E2 regulates cardiac growth through β-catenin in a strain-specific manner. Collectively, we identified a molecular mechanism that demonstrates a divergent response of mouse sub-strains to E2.